Quantcast
Last updated on April 18, 2014 at 10:45 EDT

Latest Quinuclidines Stories

2013-05-16 04:23:41

Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...

2013-03-13 15:42:56

Scientists are reporting an advance toward overcoming a major barrier to tapping the potential of traditional Chinese medicine (TCM) and India's Ayurvedic medicine in developing new and more effective modern drugs. Their report appears in ACS' Journal of Chemical Information and Modeling. Andreas Bender and colleagues explain that TCM has made key contributions to modern medicine. In the world's largest international clinical trial, for instance, scientists concluded that Artesunate, a...

2012-11-27 08:28:54

ALISO VIEJO, Calif., Nov. 27, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary results for the quarter ended September 30, 2012. Financial Update Based on preliminary results for the fourth fiscal quarter ended September 30, 2012, Avanir estimates: Gross revenue for NUEDEXTA® of $15.4 million, representing an increase of approximately 26% over the prior quarter Total operating expenses, excluding cost of product sales and non-cash...

2012-09-11 12:40:01

Scientists at The University of Nottingham say adverse side-effects caused by the anti-parasitic drug quinine in the treatment of malaria could be controlled by what we eat. The research, carried out by Nottingham scientists on the University´s campuses in the UK and Malaysia, indicates that natural variation in our levels of the amino acid, tryptophan, has a marked bearing on how we respond to quinine treatment. It appears that the lower our levels of tryptophan the more likely it is...

2012-09-04 02:29:42

ALISO VIEJO, Calif., Sept. 4, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. "Alzheimer's disease can cause a person to exhibit marked behavioral changes that are difficult for caregivers to manage. These symptoms can include agitation, hostility, anger, and...

2012-08-03 02:24:14

ALISO VIEJO, Calif., Aug. 3, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that an additional patent covering Avanir's NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) product has been listed in the U.S. Food and Drug Administration's (FDA) Orange Book. The Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant, seeking FDA approval for a generic version of NUEDEXTA prior to expiration of the patent, to notify Avanir...

2012-07-02 02:24:06

( ) ALISO VIEJO, Calif., July 2, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA®, further expanding the intellectual property portfolio for the company's lead commercial asset. This asset is a dual sigma-1 and NMDA receptor modulator that is approved for the treatment of pseudobulbar affect (PBA), and is in clinical development for...

2011-06-07 00:00:30

Motion sickness affects 1 in 6 dogs; Pfizer Animal Health urges owners to consult veterinarians for solutions on how to manage the condition. Madison, NJ (PRWEB) June 06, 2011 With the summer travel season in full swing, many dog owners now face a dilemma about traveling: canine motion sickness. More than one in six dogs in the United States suffer from vomiting caused by motion sickness, leading many families to curb travel plans or leave the family dog behind. Indeed, 82 percent of dog...

2010-02-22 17:28:59

STANFORD, Calif. "” Most cases of muscle cramps never get reported to public health authorities, so it's difficult to say how common they are. But you probably know someone who's had them. You've probably had them, too. And the older you get, the more likely you're having one right now. Until not very long ago, quinine "” a bitter-tasting substance sometimes associated with tonic water that was once the world's mainstay treatment for malaria "” was also the drug of choice...

2009-09-09 03:20:00

LUGANO, Switzerland, September 9 /PRNewswire/ -- As part of the Helsinn Group's development strategy, William Mann, PhD, has been appointed as new CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. William Mann, PhD, was already Chief Operating Officer of the recently acquired Helsinn Therapeutics, and has held leadership positions in a Swiss multinational with positions in Business Development and in Research. Moreover, Helsinn announces that Mr. William Brown has been...